Oral Bioavailability of Posaconazole in Fasted Healthy Subjects
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background and objective
Posaconazole is a potent, extended-spectrum triazole antifungal agent currently in clinical development for the treatment of invasive fungal infections. This study was conducted to compare the bioavailability and resulting serum concentrations of posaconazole 800mg following administration of three different dose regimens to fasting adults.
This was a randomised, open-label, three-way crossover study.
Subjects fasted 12 hours before and 48 hours after the administration of posaconazole oral suspension (800mg) given as a single dose (regimen A), 400mg every 12 hours (regimen B) or 200mg every 6 hours (regimen C). Plasma posaconazole concentrations were determined for 48 hours after the initial dose and subjects completed a 1-week washout period between treatment regimens. A one-compartment oral model with first-order rate of absorption and first-order rate of elimination was fitted to the plasma concentration-time data. Differences in exposure were investigated by allowing the bioavailability fraction to vary among regimens.
A total of 18 healthy men were enrolled in and completed the study.
Main outcome measures and results
Posaconazole relative bioavailability was estimated to be significantly different among regimens (p < 0.0001) and increased with the number of doses, such that regimen B/regimen A = 1.98 ± 0.35, representing a 98% increase, and regimen C/regimen A = 3.20 ± 0.69, or a 220% increase. With use of the one-compartment model, the population steady-state values for area under the concentration-time curve over 24 hours were predicted to be 3900, 7700 and 12 400 μg · h/L, with average plasma concentrations of 162, 320 and 517 μg/L for regimens and C, respectively.
These data suggest that divided daily dose administration (every 12 or 6 hours) significantly increases posaconazole exposure under fasted conditions.
- Carrillo, A.J., Guarro, J. (2001) In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 45: pp. 2151-3 CrossRef
- Connolly, P., Wheat, L.J., Schnizlein-Bick, C. (2000) Comparison of a new triazole, posaconazole, with itraconazole and amphotericin for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. Antimicrob Agents Chemother 44: pp. 2604-8 CrossRef
- Dannaoui, E., Meletiadis, J., Mouton, J.W. (2003) In vitro susceptibilities of Zygomycetes to conventional and new antifungals. J Antimicrob Chemother 51: pp. 45-52 CrossRef
- Gonzalez, G.M., Sutton, D.A., Thompson, E. (2001) In vitro activities of approved and investigational antifungal agents against 44 clinical isolates of basidiomycetous fungi. Antimicrob Agents Chemother 45: pp. 633-5 CrossRef
- Lutz, J.E., Clemons, K.V., Aristizabal, B.H. (1997) Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob Agents Chemother 41: pp. 1558-61
- Manavathu, E.K., Cutright, J.L., Loebenberg, D. (2000) A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 46: pp. 229-34 CrossRef
- Perfect, J.R., Cox, G.M., Dodge, R.K. (1996) In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 40: pp. 1910-3
- Pfaller, M.A., Messer, S.A., Hollis, R.J. (2002) Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 46: pp. 1032-7 CrossRef
- Sugar, A.M., Liu, X.P. (1996) In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 40: pp. 1314-6
- Uchida, K., Yokota, N., Yamaguchi, H. (2001) In vitro antifungal activity of posaconazole against various pathogenic fungi. Int J Antimicrob Agents 18: pp. 167-72 CrossRef
- Laverdiere, M., Hoban, D., Restieri, C. (2002) In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 50: pp. 119-23 CrossRef
- Fothergill, A.W. (1996) Identification of dematiaceous fungi and their role in human disease. Clin Infect Dis 22: pp. S179-84 CrossRef
- Cacciapuoti, A., Loebenberg, D., Corcoran, E. (2000) In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother 44: pp. 2017-22 CrossRef
- Manavathu, E.K., Abraham, O.C., Chandrasekar, P.H. (2001) Isolation and in vitro susceptibility to amphotericin itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus. Clin Microbiol Infect 7: pp. 130-7 CrossRef
- Petraitiene, R., Petraitis, V., Groll, A.H. (2001) Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 45: pp. 857-69 CrossRef
- Heimark, L., Shipkova, P., Greene, J. (2002) Mechanism of azole antifungal activity as determined by liquid chromatographic/mass spectrometric monitoring of ergosterol biosynthesis. J Mass Spectrom 37: pp. 265-9 CrossRef
- Chiller, T.M., Stevens, D.A. (2000) Treatment strategies for Aspergillus infections. Drug Resist Updat 3: pp. 89-97 CrossRef
- Graybill, J.R. (2000) Changing strategies for treatment of systemic mycoses. Braz J Infect Dis 4: pp. 47-54
- Woo, S.B., Sonis, S.T., Monopoli, M.M. (1993) A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 72: pp. 1612-7 CrossRef
- Arikan, S., Rex, J.H. (2000) New agents for treatment of systemic fungal infections. Opin Emerg Drugs 5: pp. 135-60 CrossRef
- Marr, K.A., Carter, R.A., Crippa, F. (2002) Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34: pp. 909-17 CrossRef
- Oakley, K.L., Morrisey, G., Denning, D.W. (1997) Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconzaole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother 41: pp. 1504-7
- Courtney, R., Pai, S., Laughlin, M. (2003) Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 47: pp. 2788-95 CrossRef
- Courtney, R., Wexler, D., Radwanski, E. (2004) Effect of food on the relative bioavailability of two oral fomulations of posaconazole in healthy adults. Br J Clin Pharmacol 57: pp. 218-22 CrossRef
- Saha, P., Kou, J. (2000) Effect of solubilizing excipients on permeation of poorly water-soluble compounds across Caco-2 monolayers. Eur J Pharm Biopharm 50: pp. 403-11 CrossRef
- Nomeir, A.A., Kumari, P., Hilbert, M.J. (2000) Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother 44: pp. 727-31 CrossRef
- Ezzet, F., Wexler, D., Courtney, R. (2001) The pharmacokinetics of posaconazole in neutropenic oncology patients [abstract no. A26].
- Oral Bioavailability of Posaconazole in Fasted Healthy Subjects
Volume 44, Issue 2 , pp 211-220
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors